Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren plus hydrochlorothiazide versus hydrochlorothiazide alone in essential hypertension inadequately responsive to hydrochlorothiazide
2005-004580-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren and hydrochlorothiazide in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Jul 2006; status: completed.
02
Drugs
aliskirenhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2005-004580-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004580-40.